Vitality Watch

Dossier pubmed preclinical 01-jul-2026
Animal model, organoid, or cell-culture result — not yet human

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Key claim: An AI-optimized antisense oligonucleotide (LM2556) targeting the LMNA 3’UTR selectively reduced progerin and farnesylated pre-lamin A, improved cardiovascular pathology, and extended median lifespan by 82.86% in progeroid mouse models.

Abstract

BACKGROUND: Progeroid laminopathies (PLs), including Hutchinson-Gilford progeria syndrome (HGPS), are rare premature aging disorders in which cardiovascular complications drive early mortality. Antisense oligonucleotides (ASOs) represent a promising therapeutic strategy, yet optimal design principles and their impact on cardiovascular pathology remain insufficiently defined. METHODS: We developed an AI-driven pipeline to design ASOs targeting the 3’UTR of LMNA transcripts to suppress processing-deficient pathogenic lamin A isoforms. Lead candidates were evaluated in patient-derived induced pluripotent stem cell-derived cardiomyocytes (PL-iCMs), 3D cardiac organoids, and LMNA transgenic mouse models. Efficacy, toxicity, and systemic transcriptional responses were assessed using molecular, histological, and serum biochemical analyses. FINDINGS: The optimized ASO, LM2556, selectively reduced progerin and farnesylated pre-lamin A expression while preserving lamin C. LM2556 mitigated cellular senescence and improved structural and functional phenotypes in PL-iCMs and cardiac organoids. In vivo, LM2556 decreased pathogenic lamin A isoforms across multiple tissues without evidence of hepatotoxicity or nephrotoxicity. Long-term administration ameliorated progeroid features, improved cardiovascular pathology, extended median lifespan by 82.86%, and enhanced overall healthspan in LMNA transgenic mice. CONCLUSIONS: These findings establish an AI-based framework for therapeutic ASO design and provide proof-of-concept evidence that targeting the 3’UTR of LMNA transcripts can effectively suppress pathogenic lamin A isoforms and ameliorate systemic progeroid phenotypes. FUNDING: This work was funded by the National Natural Science Foundation of China (82450116 and 82502251).

Why this matters

AI-in-longevity discourse is dominated by biomarker and brain-age tooling; this finding is a rare concrete case of generative/optimization AI producing a candidate therapeutic with a large preclinical effect size in a progeroid model. It sharpens the distinction between AI-as-analytics (where most current trend momentum sits) and AI-as-drug-designer, while the evidence remains mouse-only for a rare pediatric syndrome rather than general aging.

Source

Link

Briefing card

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.
Stage: preclinical · pubmed · 01-jul-2026

An AI-optimized antisense oligonucleotide (LM2556) targeting the LMNA 3'UTR selectively reduced progerin and farnesylated pre-lamin A, improved cardiovascular pathology, and extended median lifespan by 82.86% in progeroid mouse models.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.medj.2026.101193

build build 880 · 2bcef25 · 2026-11-18